Krivoborodov G G, Tur E I
Department of Urology and Andrology, Medical Faculty of N.I. Pirogov RNRMU of Minzdrav of Russia, Moscow.
Department of Urology, Russian Gerontology Research and Clinical Center, Moscow, Russia.
Urologiia. 2017 Apr(1):82-88. doi: 10.18565/urol.2017.1.82-88.
Overactive bladder (OAB) is a common and bothersome condition manifested by urgency, frequent urination, significantly impairing patients quality of life. The article presents an overview of the evidence on pharmacotherapy of neurogenic and idiopathic OAB. Selective M3 receptor blockers have been shown to be the medications of choice in treating these patients. Many studies have shown that solifenacin 10 mg is a starting dose for patients with OAB. Mirabegron (Betmiga) is the only 3-adrenergic receptor agonist approved for primary treatment of OAB patients refractory to anticholinergics or have their side effects. It seems promising to use this drug, both as monotherapy and concurrently with anticholinergic agents to improve treatment results in patients with idiopathic and neurogenic OAB.
膀胱过度活动症（OAB）是一种常见且令人困扰的病症，表现为尿急、尿频，严重影响患者的生活质量。本文概述了神经源性和特发性OAB药物治疗的相关证据。选择性M3受体阻滞剂已被证明是治疗这些患者的首选药物。许多研究表明，索利那新10mg是OAB患者的起始剂量。米拉贝隆（贝坦利）是唯一被批准用于对抗胆碱能药物难治或有副作用的OAB患者进行一线治疗的β-肾上腺素能受体激动剂。单独使用或与抗胆碱能药物联合使用该药物，似乎有望改善特发性和神经源性OAB患者的治疗效果。
